BGNE - BeiGene - Stock Price & Dividends
Exchange: USA Stocks • Country: Cayman Islands • Currency: USD • Type: Common Stock • ISIN: US07725L1026
Cancer, Oncology, Medicines, Pharmaceuticals, Treatments
BeiGene Ltd. is a biotech company focused on developing innovative cancer treatments. With a presence in the United States, China, Europe, and other international markets, the company is committed to improving the lives of cancer patients worldwide.
The company's commercial-stage products include BRUKINSA, a targeted therapy for blood cancers; TEVIMBRA, an immunotherapy for solid tumors and blood cancers; and PARTRUVIX, a potential treatment for various solid tumors. These products are designed to address specific molecular mechanisms driving cancer growth and progression.
BeiGene's clinical-stage pipeline is equally impressive, with multiple candidates in various stages of development. These include BGB-11417, a potential treatment for blood cancers; BGB-16673, a novel BTK-targeting compound; and Ociperlimab, a TIGIT inhibitor being evaluated for its potential in treating solid tumors. The company is also exploring bispecific antibodies, such as Zanidatamab, which targets HER2-positive cancers.
In addition to its clinical-stage programs, BeiGene has a robust preclinical pipeline, with multiple candidates in early-stage development. The company has established partnerships with various organizations, including Ensem Therapeutics, Shandong Luye Pharmaceutical, and Amgen, to advance its research and development efforts.
Founded in 2010, BeiGene Ltd. is headquartered in Camana Bay, the Cayman Islands. With a strong focus on innovation and collaboration, the company is poised to make a significant impact in the field of oncology. For more information, visit their website at https://www.beigene.com.
Drawdown (Underwater) Chart
Overall Trend and Yearly Seasonality
BGNE Stock Overview
| Market Cap in USD | 15,627m |
| Sector | Healthcare |
| Industry | Biotechnology |
| GiC SubIndustry | Biotechnology |
| TER | 0.00% |
| IPO / Inception | 2016-02-03 |
BGNE Stock Ratings
| Growth 5y | -5.90 |
| Fundamental | -53.1 |
| Dividend | 0.00 |
| Rel. Performance vs Sector | -0.81 |
| Analysts | 4.55/5 |
| Fair Price Momentum | 142.32 USD |
| Fair Price DCF | - |
BGNE Dividends
| Dividend Yield 12m | 0.00% |
| Yield on Cost 5y | 0.00% |
| Dividends CAGR 5y | 0.00% |
| Payout Consistency | 0.0% |
BGNE Growth Ratios
| Growth 12m | -27.80% |
| Growth Correlation 12m | -60% |
| Growth Correlation 3m | -25% |
| CAGR 5y | 3.66% |
| CAGR/Mean DD 5y | 0.11 |
| Sharpe Ratio 12m | -0.68 |
| Alpha vs SP500 12m | -46.97 |
| Beta vs SP500 5y weekly | 0.89 |
| ValueRay RSI | 88.61 |
| Volatility GJR Garch 1y | 44.22% |
| Price / SMA 50 | 4.44% |
| Price / SMA 200 | -0.83% |
| Current Volume | 101.5k |
| Average Volume 20d | 255.3k |
External Links for BGNE Stock
Wall Street Journal • Benzinga • Yahoo Finance
Tweets
X • Stocktwits
Fund Manager Positions
Dataroma • Stockcircle
As of July 27, 2024, the stock is trading at USD 162.54 with a total of 101,487 shares traded.
Over the past week, the price has changed by +5.04%, over one month by +10.99%, over three months by +5.83% and over the past year by -24.12%.
According to ValueRays Forecast Model, BGNE BeiGene will be worth about 157.4 in July 2025. The stock is currently trading at 162.54. This means that the stock has a potential downside of -3.16%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 268.2 | 65.0 |
| Analysts Target Price | 292.5 | 80.0 |
| ValueRay Target Price | 157.4 | -3.16 |